2018
The Telomerase Complex Directly Controls Hematopoietic Stem Cell Differentiation and Senescence in an Induced Pluripotent Stem Cell Model of Telomeropathy
SUSHAMA JOSE, Shyam, Federico TIDU, Petra LÁZNIČKOVÁ, Tomáš KEPÁK, Kamila BENDICKOVA et. al.Základní údaje
Originální název
The Telomerase Complex Directly Controls Hematopoietic Stem Cell Differentiation and Senescence in an Induced Pluripotent Stem Cell Model of Telomeropathy
Autoři
SUSHAMA JOSE, Shyam (356 Indie, domácí), Federico TIDU (380 Itálie, domácí), Petra LÁZNIČKOVÁ (203 Česká republika, domácí), Tomáš KEPÁK (203 Česká republika), Kamila BENDICKOVA (203 Česká republika) a Jan FRIČ (203 Česká republika, garant)
Vydání
FRONTIERS IN GENETICS, LAUSANNE, FRONTIERS MEDIA SA, 2018, 1664-8021
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10603 Genetics and heredity
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.517
Kód RIV
RIV/00216224:14110/18:00104194
Organizační jednotka
Lékařská fakulta
UT WoS
000443045400001
Klíčová slova anglicky
telomerase imbalance; hematopoiesis; immune function; immunosenescence; iPSC; dyskeratosis congenita; myelopoiesis
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 10. 8. 2021 08:47, Mgr. Tereza Miškechová
Anotace
V originále
Telomeropathies are rare disorders associated with impaired telomere length control mechanisms that frequently result from genetic mutations in the telomerase complex. Dyskeratosis congenita is a congenital progressive telomeropathy in which mutation in the telomerase RNA component (TERC) impairs telomere maintenance leading to accelerated cellular senescence and clinical outcomes resembling premature aging. The most severe clinical feature is perturbed hematopoiesis and bone-marrow failure, but the underlying mechanisms are not fully understood. Here, we developed a model of telomerase function imbalance using shRNA to knockdown TERC expression in human induced pluripotent stem cells (iPSCs). We then promoted in vitro hematopoiesis in these cells to analyze the effects of TERC impairment. Reduced TERC expression impaired hematopoietic stem-cell (HSC) differentiation and increased the expression of cellular senescence markers and production of reactive oxygen species. Interestingly, telomere length was unaffected in shTERC knockdown iPSCs, leading to conclusion that the phenotype is controlled by non-telomeric functions of telomerase. We then assessed the effects of TERC-depletion in THP-1 myeloid cells and again observed reduced hematopoietic and myelopoietic differentiative potential. However, these cells exhibited impaired telomerase activity as verified by accelerated telomere shortening. shTERC-depleted iPSC-derived and THP-1-derived myeloid precursors had lower phagocytic capacity and increased ROS production, indicative of senescence. These findings were confirmed using a BIBR1532 TERT inhibitor, suggesting that these phenotypes are dependent on telomerase function but not directly linked to telomere length. These data provide a better understanding of the molecular processes driving the clinical signs of telomeropathies and identify novel roles of the telomerase complex other than regulating telomere length.